A Randomized, placebo-controlled study of SRT2104, a SIRT1 activator, in patients with moderate to severe psoriasis

PLoS ONE

Volumn 10, Issue 11, 2015, Pages

  Krueger, James G ^a   Suarez Fariñas, Mayte ^a   Cueto, Inna ^a   Khacherian, Artemis ^a   Matheson, Robert ^b   Parish, Lawrence C ^c   Leonardi, Craig ^d   Shortino, Denise ^e   Gupta, Akanksha ^e   Haddad, Jonathan ^e   Vlasuk, George P ^e   Jacobson, Eric W ^e  

^a ROCKEFELLER UNIVERSITY   (United States)

^b OREGON MEDICAL RESEARCH CENTER   (United States)

^c Paddington Testing Company Inc   (United States)

^d Central Dermatology   (United States)

^e GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPSORIASIS AGENT; INTERLEUKIN 17; PLACEBO; SIRTUIN 1; SRT 2104; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ENZYME ACTIVATOR; FUSED HETEROCYCLIC RINGS; SIRT1 PROTEIN, HUMAN; SRT2104;

ADULT; AGED; ARTICLE; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION; HEADACHE; HUMAN; HUMAN TISSUE; KERATINOCYTE; LIMB PAIN; MALE; MULTICENTER STUDY; NAUSEA; PANCREATITIS; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRURITUS; PSORIASIS; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN BIOPSY; UPPER RESPIRATORY TRACT INFECTION; VOMITING; CLINICAL TRIAL; METABOLISM; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; DOUBLE-BLIND METHOD; ENZYME ACTIVATORS; FEMALE; HETEROCYCLIC COMPOUNDS, 2-RING; HUMANS; MALE; MIDDLE AGED; PSORIASIS; SIRTUIN 1; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84953288368     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0142081     Document Type: Article

References (18)

1. Blander G, Guarente L. The Sir2 family of protein deacetylases. Annu Rev Biochem. 2004; 73: 417-435. doi: 10.1146/annurev.biochem.73.011303.073651
2. Michan S, Sinclair D. Sirtuins in mammals: insights into their biological function. Biochem J. 2007; 404: 1-13. BJ20070140 [pii]; doi: 10.1042/BJ20070140
3. Lavu S, Boss O, Elliott PJ, Lambert PD. Sirtuins-novel therapeutic targets to treat age-associated diseases. Nat Rev Drug Discov. 2008; 7: 841-853. nrd2665 [pii]; doi: 10.1038/nrd2665
4. Ng PY, Bernis Jr, Disch JA, Vu CB, Oalman CJ, Lynch AV, et al. The Identification of the SIRT1 Activator SRT2104 as a Clinical Candidate. Lett Drug Design Discov. 2013; 10: 793-797.
5. Zaba LC, Fuentes-Duculan J, Eungdamrong NJ, Johnson-Huang LM, Nograles KE, White TR, et al. Identification of TNF-related apoptosis-inducing ligand and other molecules that distinguish inflammatory from resident dendritic cells in patients with psoriasis. J Allergy Clin Immunol. 2010; 125: 1261-1268. S0091-6749(10)00542-7 [pii]; doi: 10.1016/j.jaci.2010.03.018
6. Carlin CS, Feldman SR, Krueger JG, Menter A, Krueger GG. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol. 2004; 50: 859-866. doi: 10.1016/j.jaad.2003.09.014;S0190962203033231 [pii].
7. Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. J Am Acad Dermatol. 2004; 51: 563-569. doi: 10.1016/j.jaad.2004.04.012;S0190962204010886 [pii].
8. Suarez-Farinas M, Pellegrino M, Wittkowski KM, Magnasco MO. Harshlight: a "corrective make-up" program for microarray chips. BMC Bioinformatics.2005; 6: 294. 1471-2105-6-294 [pii]; doi: 10.1186/1471-2105-6-294
9. Wu Z, Irizarry RA. Preprocessing of oligonucleotide array data. Nat Biotechnol. 2004; 22: 656-658.
10. Suarez-Farinas M, Li K, Fuentes-Duculan J, Hayden K, Brodmerkel C, Krueger JG. Expanding the psoriasis disease profile: interrogation of the skin and serum of patients with moderate-to-severe psoriasis. J Invest Dermatol.2012; 132: 2552-2564. jid2012184 [pii]; doi: 10.1038/jid.2012.184
11. Hoffmann E, Wald J, Lavu S, Roberts J, Beaumont C, Haddad J, et al. Pharmacokinetics and tolerability of SRT2104, a first-in-class small molecule activator of SIRT1, after single and repeated oral administration in man. Br J Clin Pharmacol.2013; 75: 186-196. doi: 10.1111/j.1365-2125.2012.04340.x
12. Blyth C, Still H. Binomial confidence intervals. Journal of the American Statistical Association.1983; 78:108-116.
13. Tian S, Krueger JG, Li K, Jabbari A, Brodmerkel C, Lowes MA, et al. Meta-analysis derived (MAD) transcriptome of psoriasis defines the "core" pathogenesis of disease. PLoS One. 2012; 7: e44274. doi: 10.1371/journal.pone.0044274;PONE-D-12-14762 [pii].
14. Nograles KE, Zaba LC, Guttman-Yassky E, Fuentes-Duculan J, Suarez-Farinas M, Cardinale I, Khatcherian A, et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol. 2008; 159: 1092-1102. BJD8769 [pii]; doi: 10.1111/j. 1365-2133.2008.08769.x
15. Gibbs S, Fijneman R, Wiegant J, van Kessel AG, van De PP, Backendorf C. Molecular characterization and evolution of the SPRR family of keratinocyte differentiation markers encoding small proline-rich proteins. Genomics. 1993; 16: 630-637. S0888-7543(83)71240-1 [pii]; doi: 10.1006/geno.1993.1240
16. Jackson B, Tilli CM, Hardman MJ, Avilion AA, MacLeod MC, Ashcroft GS, et al. Late cornified envelope family in differentiating epithelia-response to calcium and ultraviolet irradiation. J Invest Dermatol. 2005; 124: 1062-1070. JID23699 [pii]; doi: 10.1111/j.0022-202X.2005.23699.x
17. Daubener W, MacKenzie CR. IFN-gamma activated indoleamine 2, 3-dioxygenase activity in human cells is an antiparasitic and an antibacterial effector mechanism. Adv Exp Med Biol. 1999; 467: 517-524.
18. Chiricozzi A, Guttman-Yassky E, Suarez-Farinas M, Nograles KE, Tian S, Cardinale I, Chimenti S, et al. Integrative responses to IL-17 and TNF-alpha in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol.2011; 131: 677-687. jid2010340 [pii]; doi: 10. 1038/jid.2010.340